Navigation Links
Drug for Acute Respiratory Distress May Do More Harm Than Good: Study
Date:12/12/2011

SUNDAY, Dec. 11 (HealthDay News) -- A study assessing intravenous infusion of the drug salbutamol in patients with acute respiratory distress syndrome was halted because the treatment did not improve patient outcomes and was associated with an increased risk of death, researchers say.

Acute respiratory distress syndrome (ARDS) occurs in about 14 percent of patients who require being placed on mechanical ventilation. The death rate among patients with ARDS is high -- 40 to 60 percent -- and survivors have a substantial decrease in their quality of life.

However, "routine use of [beta-2] agonist therapy in mechanically ventilated patients with ARDS cannot be recommended," the researchers wrote in an article published in the Dec. 12 online edition of The Lancet.

The British study included 326 patients who received either salbutamol (also known as albuterol) or a placebo within 72 hours of developing ARDS, and the treatment continued for up to seven days. But the study was stopped after 55 (34 percent) of the 161 patients in the salbutamol group died, compared with 38 (23 percent) of the 163 patients in the placebo group.

Overall, the death rate was 47 percent higher in the salbutamol group than in the placebo group, the report indicated.

In addition, patients in the salbutamol group had fewer ventilator-free days and organ failure-free days than those in the placebo group.

"Our findings show that intravenous salbutamol given to patients with early ARDS significantly increased 28-day mortality, and reduced ventilator-free days and duration of organ support compared with those given placebo," Fang Gao Smith and Gavin Perkins of the University of Warwick, and colleagues, explained in a journal news release.

The authors added that the therapy was "poorly tolerated" by patients because it was linked to heart rhythm abnormalities and lactic acidosis (a dangerous buildup of lactic acid in the blood). "These findings were unexpected," the researchers noted.

The findings of the cancelled study may be sufficient to change treatment of patients with ARDS, Dr. B. Taylor Thompson, of Massachusetts General Hospital and Harvard Medical School, wrote in an accompanying editorial.

"[Beta-2] agonist treatment in patients with ARDS should be limited to the treatment of clinically important reversible airway obstruction and should not be part of routine care," Thompson recommended.

More information

The U.S. National Heart, Lung, and Blood Institute has more about acute respiratory distress syndrome.

-- Robert Preidt

SOURCE: The Lancet, news release, Dec. 11, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Few With Acute Kidney Injury See Specialists, Study Finds
2. TAST 2011 -- Thrombolysis and Acute Stroke Treatment in 2011: Preparing for the next decade
3. Dendritic cells protect against acute pancreatitis
4. FDA funds Rochester researchers to give chronic and acute pain clinical trials a makeover
5. Unsaturated fat breakdown leads to complications of acute pancreatitis in obese patients
6. Miriam Hospital researchers pilot new acute hepatitis C screening strategy for HIV-infected patients
7. Death Rate Higher in Minorities With Acute Leukemia
8. Regional differences in the care of acute stroke patients
9. Alcohol consumption in relation to acute pancreatitis
10. Drinking just 1 measure of spirits increases the risk of acute pancreatitis
11. $12 million NIH grant to study acute lung injury
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug for Acute Respiratory Distress May Do More Harm Than Good: Study
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to ... public health departments have been awarded national accreditation through the Public Health ... the expanding network of communities across the nation whose health departments meet rigorous ...
(Date:3/23/2017)... ... March 23, 2017 , ... PAINWeekEnd (PWE) Oklahoma City, on ... Avenue, will be an educational and exciting program providing busy clinicians and allied ... chronic pain. , Oklahoma is in a healthcare crisis. The state ranks 46th ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... The MBI “Hall of Fame” recognizes the ... acts have had a significant impact on the careers of all others involved. ... Inc. was inducted into the MBI’s Hall of Fame. The induction took place during ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... families and businesses of the Norwalk and Vermillion areas, celebrates the newest ... (N.O.R.A.) is a nonprofit, community-based substance abuse prevention and peer recovery support ...
(Date:3/23/2017)... ... March 23, 2017 , ... Benefits delivery trailblazer, ... app and centralized benefits dashboard solving one of the top frustrations in employee ... For the first time, employees can access up-to-date information and account balances for ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... March 24, 2017 According to a new report published ... Industry Forecast, 2014-2022," the spine bone stimulators market was valued at $562 million ... a CAGR of 3.6% during the forecast period. ... ... Logo ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... report to their offering. ... Pain Management in the U.S.: Consumer ... pain, emphasizing consumer survey analysis, including trends over time. The ... have selected illnesses/conditions strongly associated with physical pain and pain ...
(Date:3/24/2017)... FinancialBuzz.com News Commentary  ... According to new data published Arcview ... legal cannabis market is projected to continue to grow at ... the current presidential administration. The report created by Arcview,s data ... growth in this industry are the passage and subsequent implementation ...
Breaking Medicine Technology: